(PDF) P011 Concurrent ALK/EGFR Alterations in Chinese Lung

P011 Concurrent ALK/EGFR Alterations in Chinese Lung Cancers: Frequency, Clinical Features, and Differential Response to Therapy

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.10.035

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

December 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.01-96 Concurrent ALK/EGFR Alterations in Chinese Lung Cancers: Frequency, Clinical Features, and Differential Response to Therapy

Journal of Thoracic Oncology

Respiratory Medicine

English

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-mutated Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

MA16.04 Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers With Concurrent TP53 and RB1 Mutations

Journal of Thoracic Oncology

Respiratory Medicine

English

P071 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.03-07 Co-Occurring Genomic Alterations in EGFR Altered Chinese Lung Adenocarcinoma Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology

Cancer Research

English

P1.01-58 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.01-117 Concurrent Gene Alterations in Treatment-Naïve EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

EGFR Alterations and Response to Anti-Egfr Therapy: Is It a Matter of Gene Amplification or Gene Copy Number Gain?

British Journal of Cancer

Cancer Research

English